Medical Devices Regulation 2017/745

The EU Medical Devices Regulation 2017/745 (MDR) is a binding regulation that replaced the Medical Devices Directive 93/42/EEC. It applies to all devices intended for medical purposes, including diagnostic software. The regulation categorizes devices into four risk classes (I, IIa, IIb, III) and mandates strict requirements for technical documentation, clinical evaluation, and post-market surveillance. Unlike the previous directive, MDR requires a higher level of clinical evidence and continuous monitoring of the device's performance throughout its lifecycle. For companies operating in the EU, compliance is not optional—it is a prerequisite for CE marking. The regulation also introduces the Unique Device Identification (UDI) system to improve traceability across the supply chain, aligning with international trends toward digital product-level transparency. This shift directly impacts the risk-adjusted-return-on-investment (ROI)--calculation for medical device manufacturers.

Implementation of MDR in a corporate setting typically follows a four-step progression. Step 1: Regulatory Classification—using Annex VIII rules to determine the device class, which dictates the level of oversight. Step 2: Risk Management Integration—applying ISO 14971 to identify hazards, estimate risks, and implement control measures. Step 3: Technical Documentation—compiling the General Safety and Performance Requirements (GSPR)--a new concept under MDR-to-prove compliance. Step 4: Post-Market Surveillance—establishing a system to collect and analyze real-world performance data. A Taiwanese manufacturer of orthopedic implants, for instance, might be closely monitored under MDR Class III requirements, requiring a notified body audit every year. By integrating these steps into the Enterprise Risk Management (ERM) framework, the company can preemptively address regulatory changes,-avoid product recalls, and manage the financial impact of compliance-related delays.

Taiwanese enterprises typically face three primary challenges. First, the 'Clinical Evidence Gap'—many SMEs lack the internal capacity to conduct the rigorous clinical investigations now required by MDR. The solution is to partner with Clinical Research Organizations (CROs) early in the development phase. Second, the 'Notified Body Bottleneck'—the shortage of EU-approved notified bodies has led to significant delays in certification. Companies should be closely monitoring the list of designated notified bodies and initiate applications at least 12-18 months before the planned market entry. Third, the 'Resource Strain'—MDR compliance requires significant investment in quality management systems (QMS) and regulatory personnel. The strategic approach is to prioritize high-revenue products for first-wave compliance while phasing in lower-risk items. Successful companies often adopt a 'compliance-by-design' philosophy, ensuring that regulatory requirements are integrated into the R&D process from the outset, rather than treated as a final check-gate.

Winners Consulting Services Co., Ltd. specializes in Medical Devices Directive 2017/745 for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact